Article
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Nature medicine - 1 Aug 2018
Bunse Lukas, Pusch Stefan, Bunse Theresa, Sahm Felix, Sanghvi Khwab, Friedrich Mirco, Alansary Dalia, Sonner Jana K, Green Edward, Deumelandt Katrin, Kilian Michael, Neftel Cyril, Uhlig Stefanie, Kessler Tobias, von Landenberg Anna, Berghoff Anna S, Marsh Kelly, Steadman Mya, Zhu Dongwei, Nicolay Brandon, Wiestler Benedikt, Breckwoldt Michael O, Al-Ali Ruslan, Karcher-Bausch Simone, Bozza Matthias, Oezen Iris, Kramer Magdalena, Meyer Jochen, Habel Antje, Eisel Jessica, Poschet Gernot, Weller Michael, Preusser Matthias, Nadji-Ohl Minou, Thon Niklas, Burger Michael C, Harter Patrick N, Ratliff Miriam, Harbottle Richard, Benner Axel, Schrimpf Daniel, Okun Jürgen, Herold-Mende Christel, Turcan Sevin, Kaulfuss Stefan, Hess-Stumpp Holger, Bieback Karen, Cahill Daniel P, Plate Karl H, Hänggi Daniel, Dorsch Marion, Suvà Mario L, Niemeyer Barbara A, von Deimling Andreas, Wick Wolfgang, Platten Michael
Abstract excerpt
The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation. Here, we identify an additional activity of R-2-HG: tumor cell-derived R-2-HG is taken up by T cells where it induces a perturbation of nuclear factor of activated T cells transcriptional activity and polyamine biosynthesis, resulting in suppression of T...
Read the complete abstract on PubMed